Antioxidant Activity and Inhibition of Human Cancer Cells by the Herbal Product, ARCOMIG

1Manuel Aregullin, 2John P. Berry and 3Linson Cadena

To assess the potential efficacy of this product, we investigated two relevant biological activities of the ARCOMIG preparation. Specifically, ARCOMIG was evaluated for inhibition of a representation of human cancer cell-lines, including colon (HT29), ovarian (SK-OV-3), mammary (SK-BR-3), renal (A498) and lung adenocarcinoma, as well as glioblastoma (U251) and lymphocytic leukemia (CEM), lines. In addition, ARCOMIG was assessed by spectrophotometric techniques for both in vitro antioxidant activity, specifically using the model free-radical, 1,1-diphenyl-2-picrylhydrazyl (DPPH) and for inhibition of intracellular reactive oxygen species (ROSs), specifically using the fluorescent indicator, 2',7'-dichlorofluorescin (DCFH). Results of these assays demonstrate that ARCOMIG moderately inhibited all cancer lines tested and was particularly active with respect to a lymphocytic leukemia line. Moreover, at concentrations well below those for which cytotoxicity was observed, ARCOMIG rapidly and potently reduced the free radical, DPPH, as well as inhibiting the intracellular production of ROSs in human colon cells. When compared to the well-recognized dietary antioxidant, resveratrol, the results suggest that the antioxidant activity of ARCOMIG may equal or even surpass the activity of this compound. Taken together, these findings are consistent with purported clinical efficacy of ARCOMIG, however, further studies are clearly needed to elucidate the putative health benefits of this herbal product.

Key words: Herbal, anticancer, antioxidant, dietary supplement, ARCOMIG

1Molecular Biology and Genetics, 245 Biotechnology Bldg., Cornell University, Ithaca, NY 14853-2703, USA
2Division of Marine Biology and Fisheries, Rosenstiel School of Marine and Atmospheric Science, University of Miami, Miami, FL, USA
3Arcomig Natural Herbs and Teas, Huntington Park, CA, USA
INTRODUCTION

The herbal preparation, ARCOMIG, is marketed and used clinically throughout Latin America as a dietary supplement and treatment for chronic and degenerative diseases, including cancer, diabetes, arthritis, high blood pressure and high cholesterol. Included among the botanical and other natural ingredients are chamomile, angelica, shaved grass, alfalfa and garlic that have been documented to contain compounds with a variety of pharmacological activities (O’Hara et al., 1998; Hernandez-Ceruelos et al., 2002; Kimura, 2005; Sarkar and Nahar, 2004; Banerjee et al., 2003; Khanum et al., 2004; Tattelman, 2005). In particular, a number of these have been suggested to have efficacy as antioxidants and potential in treatment and prevention of cancer (O’Hara et al., 1998; Hernandez-Ceruelos et al., 2002; Kimura, 2005; Sarkar and Nahar, 2004; Banerjee et al., 2003; Khanum et al., 2004; Tattelman, 2005).

To-date no published reports have detailed biological activity of ARCOMIG despite its wide use. Here we specifically report on the cytotoxicity of ARCOMIG toward human cancer cells and its in vitro and intracellular antioxidant activity.

MATERIALS AND METHODS

ARCOMIG preparation: For evaluation of biological activity, ARCOMIG was prepared as a “tea” (water extract) as described for oral administration. The undiluted tea was syringe-filtered (0.2 μm pore size) to sterilize and remove any sediment from the preparation. Aliquots of the filtered preparation were lyophilized and an approximate concentration (w/v), specifically of 95.4 mg “extracted material” per mL of tea, was determined. Data are therefore expressed as either concentration (w/v) based on this determination, or alternatively per dilution (i.e., x-fold) of the undiluted tea.

Inhibition of cancer cells: Cytotoxicity was evaluated for human cancer cell-lines, specifically including glioblastoma (U251), lung adenocarcinoma (H460), colon adenocarcinoma (HT29), ovarian adenocarcinoma (SK-OV-3), melanoma (SK-MEL-28), renal adenocarcinoma (A498), lymphocytic leukemia (CEM) and mammary adenocarcinoma (SKBR3). All cell-lines were obtained from the US National Cancer Institute Division of Cancer Treatment and Diagnosis Tumor Repository (Frederick, MD), except SKBR3 that was supplied by Dr. Maria Laux of Department of Clinical Cancer Therapy at Cornell University College of Veterinary Medicine (Ithaca, NY). Cells were cultured in RPMI 1640 medium with L-glutamine (Cambrex Bio Science Walkersville, Inc., Walkersville, MD), supplemented with either 10% fetal bovine serum or newborn calf serum and antibiotics/antimycotics (Sigma-Aldrich, St. Louis, MO) and sub-cultured twice weekly by trypsinization (except non-adherent CEM).

Cytotoxicity was evaluated for cells grown in 96-well plates and treated with serially diluted ARCOMIG. Inhibition of cell-viability was qualitatively determined based on reduction the colorimetric indicator, alamarBlue, as previously described (Berry et al., 2002, 2004; Wagner et al., 1999). Minimum inhibitory concentrations (MICs) of ARCOMIG, as a measure of relative cytotoxicity, were determined for each cell-line based on the color change from blue to red resulting from reduction of the indicator by viable cells. As appropriate, percent inhibition was determined based on the fluorescence (EX 530 nm, EM 590 nm) of the reduced indicator relative to an untreated control, as described previously (Berry et al., 2002, 2004). Fluorescence was measured using a BioTek® Synergy™ HT Multi detection Microplate Reader. Median inhibitory concentration (IC₅₀), when determined, was calculated by the “least squares method” for linear fits (R² ≥ 0.90) between percent inhibition (relative to the untreated control) and log of the concentration as described previously (Berry et al., 2004).

In vitro antioxidant activity: Antioxidant activity of ARCOMIG was measured based on the ability of the preparation to scavenge the free radical, 1,1-diphenyl-2-picrylhydrazyl (DPPH), as has been previously described (Miller et al., 2001; Koleva et al., 2002; Tarozzi et al., 2004). Briefly, 50 μL aliquots of serially diluted ARCOMIG (in water), as well as negative control of water alone, were mixed with 200 μL of 100 μM DPPH (in 80% MeOH in water) in a 96-well plate. Absorbance at 515 nm was measured every 1 minute for 30 minutes, using a Bio-Tek® Synergy™ HT Multi detection Microplate Reader (Bio-Tek® Instruments, Inc., Winooski, VT), as a measure of the reduction of DPPH. Antioxidant activity was calculated as the percent reduction of DPPH relative to the water control. A “blank” of the preparation without DPPH (i.e., 80% MeOH only) was used to subtract the background absorbance due to the color of the preparation. The well described (Aggarwal et al., 2004; Bhat et al., 2001) antioxidant, resveratrol (Sigma-Aldrich, St. Louis, MO), along with the appropriate solvent control (i.e., MeOH), was tested identically as a positive control for antioxidant activity. Median effective concentration (EC₅₀, i.e. the dilution at which DPPH is 50% reduced) was calculated for ARCOMIG using the “least squares method".

230
Intracellular antioxidant activity: The ability of ARCOMIG to inhibit intracellular reactive oxygen species (ROSs) was evaluated using 2',7'-dichlorofluorescin diacetate (DCFH-DA) as per a previously developed method (Wang and Joseph, 1999). DCFH-DA crosses cell membranes and enters cells where it is converted by intracellular esterases to DCFH. In the presence of ROSs, DCFH is oxidized to the fluorescent Dichlorofluorescein (DCF). Intracellular ROSs are measured as fluorescence of cells following treatment with an oxidizing agent (Wang and Joseph, 1999).

Specifically, inhibition of intracellular ROSs was measured using colon cells (HT29). HT29 cells were grown in a 96-well plate, as described above, until completely differentiated. Cells were treated for 24 h with serially diluted ARCOMIG, or resveratrol (as a positive control), at concentrations below those found to be cytotoxic (as discussed above). Subsequently, cells were washed with Phosphate Buffered Saline (PBS) and incubated with 5 μM DCFH-DA for 30 min. Following further washing with PBS, cells were incubated for 1 h with the tert-butyl hydrogen peroxide (t-BuOOH) which induces oxidative stress. Fluorescence of DCF in cells (EX 485 nm, EM 528 nm) was measured with a BioTek Synergy HT Multi detection Microplate Reader. Cells treated identically, but without DCFH-DA, were used as blanks to subtract background fluorescence. Inhibition of the formation of ROSs was measured as the adjusted fluorescence of treated cells (Ft) relative to that of the untreated controls (Fo), specifically using the formula 1-(Ft/Fo) x 100%. The median inhibitory concentration (IC50) was calculated based on the relationship between percent inhibition and log concentration.

RESULTS

The highest inhibition was observed for the lymphocytic leukemia line (CEM) which was inhibited at concentrations as low as 1.5 mg mL−1, equivalent to a 64-fold dilution of the undiluted tea (Table 1). Cytotoxicity for other lines tested was relatively modest. In contrast, for instance, renal (A498) and ovarian (SK-OV-3) lines were only inhibited at dilutions as high as 4-fold, or approximately 23.9 mg mL−1 (Table 1).

On the other hand, ARCOMIG was found to be a relatively potent antioxidant. For example, the tea rapidly reduced the free radical, DPPH, as a measure of antioxidant activity. The EC50 of ARCOMIG after 30 min was calculated as 90.8 μg mL−1, equivalent to a 1052-fold dilution of the undiluted tea (Fig. 1). The rate of reduction was concentration dependent. At a concentration of ARCOMIG which most closely

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>Cell Type</th>
<th>Histology</th>
<th>IC50 (mg mL−1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SK-BR-3</td>
<td>Mammary</td>
<td>Adenocarcinoma</td>
<td>11.9</td>
</tr>
<tr>
<td>SK-OV-3</td>
<td>Ovarian</td>
<td>Adenocarcinoma</td>
<td>23.9</td>
</tr>
<tr>
<td>NCI-H460</td>
<td>Lung</td>
<td>Large-cell carcinoma</td>
<td>6.0</td>
</tr>
<tr>
<td>U251</td>
<td>CNS</td>
<td>Glioblastoma</td>
<td>11.9</td>
</tr>
<tr>
<td>HT29</td>
<td>Colon</td>
<td>Adenocarcinoma, GI</td>
<td>11.9</td>
</tr>
<tr>
<td>A498</td>
<td>Renal</td>
<td>Adenocarcinoma</td>
<td>23.9</td>
</tr>
<tr>
<td>SK-MEL-28</td>
<td>Melanoma</td>
<td>Malignant melanoma</td>
<td>6.0</td>
</tr>
<tr>
<td>CEM</td>
<td>Leukemia</td>
<td>Acute lymphoblastic</td>
<td>1.5</td>
</tr>
</tbody>
</table>

Table 1: Cytotoxicity of ARCOMIG against human cancer cell-lines.

Inhibition of cells, based on reduced viability, was determined calorimetrically by the alamarBlue method. Given are the minimum inhibitory concentrations (MICs) of the prepared "tea."
previously reported by Wang et al. (1999) who measured, using the same method, approximately 30% reduction of DPH at a concentration of 20 μM resveratrol. At a concentration (i.e., 25 μM) approximating this EC_{50} reduction of DPH was more rapid than ARCOMiG, reaching more than 22% reduction within 1 min (Fig. 2). However, after 30 minutes, an almost identical percent reduction (i.e., 45%) of DPH was observed for both resveratrol and ARCOMiG, equally tested at a concentration approximating the EC_{50} (i.e., 1/1280-fold dilution, or 74.5 mg mL^{-1}; Fig. 2).

In addition to scavenging free radicals in vitro, ARCOMiG inhibited the intracellular production of ROSs (Fig. 3) in response to the oxidizer, t-BuOOH. Effect of ARCOMiG on intracellular ROSs was specifically tested using the colon adenocarcinoma line (HT29) at concentrations equal, or less than, the determined MIC (i.e., 11.9 mg mL^{-1}) for this line (Table 1). Cytotoxicity to (i.e., percent inhibition of) cells at this highest concentration was less than 20% and generally negligible. Inhibition of intracellular ROSs was dose-dependent with an IC_{50} of approximately 1.7 mg mL^{-1}, however, up to approximately 77% inhibition was observed for the highest concentration tested (i.e., 11.9 mg mL^{-1}, or 8-fold dilution). This effect was again compared to resveratrol as a known antioxidant. However, inhibition of intracellular ROSs was only observed for the highest concentration of resveratrol (i.e., 200 and 100 μM) tested, with an approximate IC_{50} of 174 μM.

**DISCUSSION**

The herbal product, ARCOMiG, is widely sold and used as a natural dietary supplement, particularly in parts of South and Central America where it is prescribed clinically for an array of preventive and curative purposes. Purported health benefits include prevention and even therapeutic treatment, of chronic and degenerative diseases including various forms of cancer, diabetes, and arthritis, as well as maintenance of general systemic and cellular health including immunostimulation, anticholesterolemic and antioxidant activity. Prepared from various herbs, no single plant or derived compound has been yet identified as the active component and health benefits of the tea are generally considered to be related to the cumulative contribution of these various components of the complex mixture. That said, preliminary chemical studies (unpublished data) have identified compounds, including bisabolol, zingerone and herniarin, with known pharmacological activity (Isaac, 1979; Silvan et al., 1996; Cavallieri et al., 2004; Kabuto et al., 2005; Kuo et al., 2005). To date, however, no published laboratory studies have described any biological activity related to the health benefits of
ARCOMIG. The present study is the first report of an evaluation of apparent pharmacological activity consistent with these purported health benefits.

Specifically, we evaluated the cytotoxicity of ARCOMIG to various human cancer cell lines. As shown in Table 1, ARCOMIG was at least marginally cytotoxic to all eight lines tested. These lines were specifically chosen, as they approximate the breadth of cell types (specifically 8 of the 9 cancer types) routinely employed by the US National Cancer Institute for evaluation of potential anticancer drugs (Shoemaker et al., 1988). The highest inhibition was observed for the lymphocytic leukemia cell-line, CEM. This is particularly relevant, as ARCOMIG has been, indeed, recommended by physicians as a natural treatment for leukemia (Dr. Carlos Ibarra de la Toba, personal communication). On the other hand, cytotoxicity to most other lines tested was generally minimal, although these results are representative of only acute, short-term (i.e., 24-48 h) exposure of cancer cells to the crude tea. To fully understand the possible effects of administration of ARCOMIG on cancer, further studies would be obviously required, including long-term in vivo studies, particularly with respect to evaluation of individual metabolites that may be accumulated following administration of the mixture.

On the other hand, considerable antioxidant activity was demonstrated for ARCOMIG, both in vitro and in a cell-based system (Fig. 1-3). ARCOMIG effectively scavenged the model free-radical, DPH, at concentrations as low as 5 μg mL⁻¹ (Fig. 1) within 30 min and within 1 min at concentrations well below levels at which it was cytotoxic to cells (Fig. 2). Furthermore, ARCOMIG was shown to inhibit the formation of ROSs in colon cells exposed to the oxidizer, H₂O₂, by up to 77% and at concentrations as low as 47 μg mL⁻¹ (Fig. 3). As these concentrations are, indeed, below the cytotoxic MICs determined for all cell lines, it is suggested that these effects could occur in vivo without presenting additional toxicity to cells.

The antioxidant activity of ARCOMIG was further compared to the known antioxidant, resveratrol, which is generally considered to be responsible for the observed health benefits (e.g., anticancer, cardio-protective properties) associated with consumption of red wine and various other foods and dietary supplements (Aggarwal et al., 2004; Bhat et al., 2001). Comparison of this pure compound to the complex mixture of ARCOMIG is not possible on a “per concentration” basis, however, the results suggest that antioxidant potential of the (as of yet) unidentified active principle(s) of ARCOMIG is likely at least as potent as resveratrol. In terms of active concentration, the EC₅₀ for the reduction of DPHI by ARCOMIG was measured as 90.8 μg mL⁻¹, compared to an EC₅₀ of 27.3 μM, or approximately 6.2 mg mL⁻¹, for resveratrol after 30 min (Fig. 1). Assuming that the antioxidant component of ARCOMIG represents no more than 7% of the crude mixture, the free-radical scavenging activity would be at least equal to that of resveratrol. Considering a single compound generally represents much less than one percent of any crude extract such as this, it is conceivable that the antioxidant potential the active principle may, in fact, be one or more order of magnitude greater than resveratrol. Likewise, though comparison of the rates of free-radical scavenging by ARCOMIG were initially lower than resveratrol, specifically when measured at concentrations approximating the EC₅₀, nearly equal percent reduction was observed after 30 min (Fig. 2). Moreover, at concentrations well below the cytotoxic MIC for HT29, similarly rapid reduction of the indicator was observed. For example, at concentrations of 0.6 mg mL⁻¹ (or 160-fold dilution) of ARCOMIG, an approximately 44% reduction was observed within 1 min, or nearly double the rate of reduction (i.e., 22.5% in 1 min) for the EC₅₀ of resveratrol. Again, considering this is a comparison of a crude mixture versus a pure compound, it is quite likely that the active component(s) of ARCOMIG is equally active as, or perhaps even considerably more active than, resveratrol.

Similarly, when the ability of ARCOMIG to inhibit intracellular ROSs was compared to resveratrol, the calculated IC₅₀ (w/v) was significantly less for the latter. However, adjusting for presumptive contribution of the active principle to the total composition of the crude extract, it is very likely that the antioxidant activity of the purified principle could be at least equal and likely higher than, that of resveratrol. Specifically, the IC₅₀ of ARCOMIG was approximately 48-times that calculated for resveratrol (i.e., 1.7 mg mL⁻¹ for ARCOMIG vs. 0.04 mg mL⁻¹ for resveratrol). If the active principle is equal or less than 2.3% of the total crude extract, it would translate to an, at least, equipotent antioxidant activity relative to resveratrol. Again, typically any single compound contributes considerably less than 1% of most crude extracts, suggesting that the antioxidant activity may very well surpass that of resveratrol.

In conclusion, though levels of cytotoxicity of ARCOMIG to cancer cells in this study were found to be relatively modest, further studies are clearly needed to elucidate any possible efficacy in relation to its purported anticancer benefits. On the other hand, it is clear that ARCOMIG is a seemingly potent antioxidant. Again, however, further studies particular focusing on isolated components of the crude herbal product, are necessary to definitively characterize this activity and its associated health benefits.
REFERENCES


